Marksans Pharma’s arm gets UK MHRA nod for Bells Healthcare All in One Oral Solution

22 Feb 2022 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Bell Sons & Co. (Druggists) has received UK MHRA’s grant for market authorization of Bells Healthcare All in One Oral Solution. Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) in UK. This is first generic approval by UK MHRA for the product.

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg. Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.


Marksans Pharma Share Price

291.60 2.10 (0.73%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.